Asset
RIPRETINIB
ZAI LAB LIMITED AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04282980 | phase2 | completed | 2020-04-23 | 2021-02-26 | Zai Lab (Shanghai) Co., Ltd. | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) |
| NCT04633122 | phase2 | completed | 2020-11-25 | 2022-07-20 | Zai Lab (Shanghai) Co., Ltd. | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib |
FDA applications (0)
This company has no applications containing this asset.